Merck’s Keytruda wins coveted FDA nod around surgery for early lung cancer—with a surprise
Fierce Pharma
OCTOBER 16, 2023
Up until this point, immune checkpoint inhibitors have been allowed to treat early-stage non-small cell lung cancer (NSCLC) either before or after surgery. The drug's label already includes an overall survival win from a key trial.
Let's personalize your content